Skip to menu Skip to content Skip to footer
Associate Professor Simone M Goldinger
Associate Professor

Simone M Goldinger

Email: 

Overview

Background

A/ Professor Simone M Goldinger is a clinician-researcher in dermatology with a subspecialty focus on skin cancer and digital health. Her work sits at the intersection of clinical dermatology, artificial intelligence, and longitudinal imaging, with a particular emphasis on non-melanoma skin cancer detection and surveillance. Her current research develops and validates equitable, data-driven approaches to skin cancer diagnosis, drawing on large-scale longitudinal datasets to improve accuracy, address algorithmic bias, and support real-world clinical implementation. A central goal is ensuring these AI-powered tools are effective across diverse patient populations and translatable into everyday clinical practice.

Earlier in her career, A/Prof Goldinger specialised in dermato-oncology, focusing on metastatic melanoma and the cutaneous toxicities associated with immune checkpoint inhibitors and targeted therapies. This background in advanced disease management provides a strong translational foundation for her current work, connecting insights from late-stage oncology to earlier detection, risk stratification, and long-term monitoring. Her research bridges clinical medicine, data science, and health equity — with the aim of improving outcomes for patients with skin cancer in Australia and beyond.

Availability

Associate Professor Simone M Goldinger is:
Available for supervision

Qualifications

  • Bachelor (Honours) of Medicine, University of Zurich
  • Masters (Research) of Medicine and Surgery and Medical Science, University of Zurich
  • Doctoral (Research), University of Zurich
  • Professional Doctorate, University of Zurich
  • Fellow, Australasian College of Dermatologists, Australasian College of Dermatologists

Research impacts

Skin cancer is the most common cancer in Australia, and early detection can save lives. A/Prof Goldinger's research is working to make skin cancer diagnosis smarter, faster, and fairer — developing AI tools that can assist clinicians in spotting cancers earlier and monitoring high-risk patients more effectively over time. A key focus is equity: ensuring that AI diagnostic systems work well for all patients, regardless of skin tone or background. By identifying and correcting for bias in these tools before they reach the clinic, this research helps reduce the risk that AI makes existing health disparities worse. Her earlier work on the skin side effects of cancer treatments — including immunotherapy and targeted therapies — has contributed to better recognition and management of these complications, helping patients stay on life-saving treatments for longer. Together, this research aims to improve outcomes for skin cancer patients across Australia, support clinicians with better decision-making tools, and ensure that advances in digital health benefit everyone equitably.

Works

Search Professor Simone M Goldinger’s works on UQ eSpace

137 works between 2006 and 2026

121 - 137 of 137 works

2012

Conference Publication

OPEN-LABEL PILOT STUDY OF VEMURAFENIB IN PREVIOUSLY TREATED METASTATIC MELANOMA (MM) PATIENTS (PTS) WITH SYMPTOMATIC BRAIN METASTASES (BM)

Dummer, R., Goldinger, S., Turtschi, C., Eggmann, N., Michielin, O., Mitchell, L., Veronese, L., Hilfiker, P. R. and Rinderknecht, J. D. (2012). OPEN-LABEL PILOT STUDY OF VEMURAFENIB IN PREVIOUSLY TREATED METASTATIC MELANOMA (MM) PATIENTS (PTS) WITH SYMPTOMATIC BRAIN METASTASES (BM). 37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna Austria, Sep 28-Oct 02, 2012. OXFORD: OXFORD UNIV PRESS.

OPEN-LABEL PILOT STUDY OF VEMURAFENIB IN PREVIOUSLY TREATED METASTATIC MELANOMA (MM) PATIENTS (PTS) WITH SYMPTOMATIC BRAIN METASTASES (BM)

2012

Journal Article

Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective <i>BRAF</i> Inhibition

Zimmer, Lisa, Hillen, Uwe, Livingstone, Elisabeth, Lacouture, Mario E., Busam, Klaus, Carvajal, Richard D., Egberts, Friederike, Hauschild, Axel, Kashani-Sabet, Mohammed, Goldinger, Simone M., Dummer, Reinhard, Long, Georgina V., McArthur, Grant, Scherag, Andre, Sucker, Antje and Schadendorf, Dirk (2012). Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. Journal of Clinical Oncology, 30 (19), 2375-2383. doi: 10.1200/JCO.2011.41.1660

Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective <i>BRAF</i> Inhibition

2012

Conference Publication

Cutaneous side effects (cAE) of vemurafenib (V): Single-center cohort study of 28 metastatic melanoma (mM) patients (pts)

Goldinger, Simone M., Rinderknecht, Jeannine Desiree, Belloni, Benedetta, Eggmann, Nina and Dummer, Reinhard (2012). Cutaneous side effects (cAE) of vemurafenib (V): Single-center cohort study of 28 metastatic melanoma (mM) patients (pts). 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 01-06, 2012. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY.

Cutaneous side effects (cAE) of vemurafenib (V): Single-center cohort study of 28 metastatic melanoma (mM) patients (pts)

2012

Journal Article

Cutaneous Lymphomas: Molecular Pathways Leading to New Drugs

Dummer, Reinhard, Goldinger, Simone M., Cozzio, Antonio, French, Lars E. and Karpova, Maria B. (2012). Cutaneous Lymphomas: Molecular Pathways Leading to New Drugs. Journal of Investigative Dermatology, 132 (3), 517-525. doi: 10.1038/jid.2011.370

Cutaneous Lymphomas: Molecular Pathways Leading to New Drugs

2012

Journal Article

Ultraviolet A and Photosensitivity during Vemurafenib Therapy

Dummer, Reinhard, Rinderknecht, Jeannine and Goldinger, Simone M. (2012). Ultraviolet A and Photosensitivity during Vemurafenib Therapy. New England Journal of Medicine, 366 (5), 480-481. doi: 10.1056/NEJMc1113752

Ultraviolet A and Photosensitivity during Vemurafenib Therapy

2012

Journal Article

First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)

von Moos, R., Seifert, B., Simcock, M., Goldinger, S. M., Gillessen, S., Ochsenbein, A., Michielin, O., Cathomas, R., Schlaeppi, M., Moch, H., Schraml, P. H., Mjhic-Probst, D., Mamot, C., Schoenewolf, N. and Dummer, R. (2012). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Annals of Oncology, 23 (2), 531-536. doi: 10.1093/annonc/mdr126

First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)

2012

Journal Article

Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs

Belloni, Benedetta, Schoenewolf, Nicola, Rozati, Sima, Goldinger, Simone M. and Dummer, Reinhard (2012). Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs. Adverse Cutaneous Drug Eruptions, 97, 191-202. doi: 10.1159/000335632

Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs

2011

Conference Publication

Final results of single-agent phase II study using the inhibitor of purine nucleoside phosphorylase (PNP) in patients suffering from advanced primary cutaneous t-cell lymphomas (CTCL)

Dummer, R., Duvic, M., Scarisbrick, J., Olsen, E., Goldinger, S., Hutchinson, K., Geskin, L., Illidge, T., Kim, Y., Giuliano, E. and Elder, J. (2011). Final results of single-agent phase II study using the inhibitor of purine nucleoside phosphorylase (PNP) in patients suffering from advanced primary cutaneous t-cell lymphomas (CTCL). MALDEN: WILEY-BLACKWELL.

Final results of single-agent phase II study using the inhibitor of purine nucleoside phosphorylase (PNP) in patients suffering from advanced primary cutaneous t-cell lymphomas (CTCL)

2011

Conference Publication

Inhibition of the MEK-kinase pathway in advanced melanoma

Dummer, R., Goldinger, S., Turtschi, C., Gisler, S., Eggmann, N. and Rinderknecht, J. (2011). Inhibition of the MEK-kinase pathway in advanced melanoma. BASEL: KARGER.

Inhibition of the MEK-kinase pathway in advanced melanoma

2011

Conference Publication

An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases

Dummer, R., Rinderknecht, J., Goldinger, S. M., Wagner, I., Mitchell, L., Veronese, M. L., Nick, S., Hilfiker, P. and Gobbi, S. (2011). An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/jco.2011.29.15_suppl.8548

An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases

2011

Journal Article

The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study

Imhof, Laurence, Goldinger, Simone M., Baumann, Katrin, Schad, Karin, French, Lars E., Roethlisberger, Peter and Dummer, Reinhard (2011). The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study. Melanoma Research, 21 (1), 80-83. doi: 10.1097/CMR.0b013e328341442d

The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study

2010

Conference Publication

First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07)

Dummer, R., Michielin, O., Seifert, B., Ochsenbein, A. F., Cathomas, R., Schlaeppi, M. R., Simcock, M., Gillessen, S., Goldinger, S. M. and von Moos, R. (2010). First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/jco.2010.28.15_suppl.8521

First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07)

2010

Conference Publication

Predictive and prognostic potential of angiogenic serum factors and circulating endothelial cells in metastatic melanoma patients receiving temozolamide plus bevacizumab (SAKK 50/07)

Fuerstenberger, G., Boneberg, E., Simcock, M., Dummer, R., Goldinger, S. M., Michielin, O., Seifert, B., Ochsenbein, A. F., Schlaeppi, M. R. and von Moos, R. (2010). Predictive and prognostic potential of angiogenic serum factors and circulating endothelial cells in metastatic melanoma patients receiving temozolamide plus bevacizumab (SAKK 50/07). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/jco.2010.28.15_suppl.8585

Predictive and prognostic potential of angiogenic serum factors and circulating endothelial cells in metastatic melanoma patients receiving temozolamide plus bevacizumab (SAKK 50/07)

2009

Journal Article

Limited value of <SUP>18</SUP>F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma

Strobel, K., Bode, B., Dummer, R., Veit-Haibach, P., Fischer, D. R., Imhof, L., Goldinger, S., Steinert, Hans C. and von Schulthess, G. K. (2009). Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 36 (11), 1774-1782. doi: 10.1007/s00259-009-1175-0

Limited value of <SUP>18</SUP>F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma

2009

Conference Publication

Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07)

Von Moos, R., Seifert, B., Ochsenbein, A., Cathomas, R., Schlaeppi, M., Gillessen, S., Schuller, J. C., Michielin, O., Goldinger, S. and Dummer, R. (2009). Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07). 15th ECCO/34th ESMO Multidisciplinary Congress, Berlin Germany, Sep 20-24, 2009. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. doi: 10.1016/S1359-6349(09)72059-2

Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07)

2007

Journal Article

Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo

Goldinger, S. M., Dummer, R., Schmid, P., Burg, G., Seifert, B. and Lauchli, S. (2007). Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. Journal of the European Academy of Dermatology and Venereology, 21 (4), 504-508. doi: 10.1111/j.1468-3083.2006.02016.x

Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo

2006

Journal Article

Excimer laser versus narrow-band UVB (311 nm) in the treatment of psoriasis vulgaris

Goldinger, Simone Maria, Dummer, Reinhard, Schmid, Peter, Vavricka, Mareike Prinz, Burg, Guenter and Laeuchli, Severin (2006). Excimer laser versus narrow-band UVB (311 nm) in the treatment of psoriasis vulgaris. Dermatology, 213 (2), 134-139. doi: 10.1159/000093852

Excimer laser versus narrow-band UVB (311 nm) in the treatment of psoriasis vulgaris

Supervision

Availability

Associate Professor Simone M Goldinger is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Media

Enquiries

For media enquiries about Associate Professor Simone M Goldinger's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au